Compare Expeditors International of Wshngtn Inc (EXPD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Summit Therapeutics Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $193.67 (market cap $25.18B), while Summit Therapeutics Inc trades at $17.21 (market cap $13.71B). The key difference: Expeditors International of Wshngtn Inc is the larger of the two by market cap, and Expeditors International of Wshngtn Inc pays a 0.84% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Summit Therapeutics Inc for 16 Days on average.
| EXPD | SMMT | |
|---|---|---|
Market Cap | $25.18B | $13.71B |
Volume | 1,003,557 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $194.12 | $26.38 |
52-Week Low | $113.13 | $12.43 |
Typical Hold Time | 43 Days | 16 Days |
Enterprise Value | $24.72B | $13.04B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $190.85, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 expected at $2.20 EPS. Revenue growth is steady, rising from $10.6B in 2024 to a projected $12.0B in 2026, while net income margins remain stable around 7.6%. Recent news highlights efficiency initiatives and airfreight demand as positive catalysts.
Outlook is mixed: strong profitability and earnings beats support upside, but a high P/E of 28.2 suggests premium valuation risks. Analyst consensus is cautious with 63.6% hold ratings, and the consensus price target of $179.43 implies potential downside. Key risks include freight market volatility and execution challenges amid economic uncertainty.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
